Ida Vanessa Döederlein Schwartz

Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study

Paul Harmatz, Roberto Giugliani, Ida Vanessa Döederlein Schwartz et al. · The Journal of Pediatrics · 2006 · 361 citations

Translational Medicine, Phase 3, Enzyme Replacement Therapy +7

Gender, Race and Parenthood Impact Academic Productivity During the COVID-19 Pandemic: From Survey to Action

Fernanda Stanisçuaski, Lívia Kmetzsch, Rossana C. Soletti et al. · Frontiers in Psychology · 2021 · 264 citations · Full text

Impact of COVID-19 on academic mothers

Fernanda Stanisçuaski, Fernanda Maciel Reichert, Fernanda P. Werneck et al. · Science · 2020 · 218 citations

Women Empowerment, Family Medicine, Motherhood Penalty +23

Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase

Paul Harmatz, Roberto Giugliani, Ida Vanessa Döederlein Schwartz et al. · Molecular Genetics and Metabolism · 2008 · 215 citations

Translational Medicine, Enzyme Replacement Therapy, Pathology +4

Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)

Stuart J. Swiedler, Michael Beck, M Bajbouj et al. · American Journal of Medical Genetics Part A · 2005 · 161 citations